Adverse effects in COVID vax: even variabilities and databases are not immune from mixing up
Medicomunicare Magazine | Health and Medical News
With the initiation of mass vaccination against COVID-19 worldwide in December 2020, regulatory agencies, academia, pharmaceutical companies, and other stakeholders are working on various safety surveillance strategies based on observational data. The ACCESS project in Europe is funded by the European Medicines Agency and includes a protocol to evaluate background rates of conditions representing potential Adverse Events